Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:BSTC NASDAQ:MGTA NASDAQ:MORF NASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.53-1.2%$5.42$3.21▼$7.18$1.59B0.733.12 million shs2.86 million shsBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/AMGTAMagenta Therapeutics$0.70-7.7%$0.53$0.32▼$2.07$42.44M2.12848,835 shs376,000 shsMORFMorphic$56.99$56.76$19.34▼$57.00$2.85B1.491.27 million shs400 shsPBYIPuma Biotechnology$4.64+3.8%$4.21$2.32▼$6.07$225.16M1.37632,918 shs455,730 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-1.21%-0.91%+9.38%+83.94%+3.49%BSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%MGTAMagenta Therapeutics0.00%0.00%0.00%0.00%0.00%MORFMorphic0.00%0.00%0.00%0.00%0.00%PBYIPuma Biotechnology+3.80%+1.75%-19.02%+35.28%+83.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.53-1.2%$5.42$3.21▼$7.18$1.59B0.733.12 million shs2.86 million shsBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/AMGTAMagenta Therapeutics$0.70-7.7%$0.53$0.32▼$2.07$42.44M2.12848,835 shs376,000 shsMORFMorphic$56.99$56.76$19.34▼$57.00$2.85B1.491.27 million shs400 shsPBYIPuma Biotechnology$4.64+3.8%$4.21$2.32▼$6.07$225.16M1.37632,918 shs455,730 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-1.21%-0.91%+9.38%+83.94%+3.49%BSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%MGTAMagenta Therapeutics0.00%0.00%0.00%0.00%0.00%MORFMorphic0.00%0.00%0.00%0.00%0.00%PBYIPuma Biotechnology+3.80%+1.75%-19.02%+35.28%+83.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.10Buy$11.7079.17% UpsideBSTCBioSpecifics Technologies 0.00N/AN/AN/AMGTAMagenta Therapeutics 0.00N/AN/AN/AMORFMorphic 0.00N/AN/AN/APBYIPuma Biotechnology 3.00Buy$7.0050.86% UpsideCurrent Analyst Ratings BreakdownLatest PBYI, BSTC, ARDX, MORF, and MGTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$14.009/2/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy8/6/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$8.00 ➝ $9.008/5/2025ARDXArdelyxUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$12.008/5/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00 ➝ $12.008/5/2025ARDXArdelyxWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.00 ➝ $14.006/18/2025ARDXArdelyxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M4.72N/AN/A$0.73 per share8.95BSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81MGTAMagenta TherapeuticsN/AN/AN/AN/A$1.23 per shareN/AMORFMorphic$520K5,490.11N/AN/A$12.31 per share4.63PBYIPuma Biotechnology$230.50M1.01$0.88 per share5.25$1.88 per share2.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.23N/A21.06N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)BSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/AMGTAMagenta Therapeutics-$76.46MN/A0.00∞N/AN/A-70.88%-57.27%N/AMORFMorphic-$152.10M-$3.50N/AN/AN/AN/A-26.62%-25.74%N/APBYIPuma Biotechnology$30.28M$0.984.7312.21N/A20.38%53.15%23.51%11/6/2025 (Estimated)Latest PBYI, BSTC, ARDX, MORF, and MGTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ABSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AMGTAMagenta TherapeuticsN/AN/AN/AN/AN/AMORFMorphicN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.444.304.03BSTCBioSpecifics TechnologiesN/A66.2466.24MGTAMagenta TherapeuticsN/A19.4919.49MORFMorphicN/A24.1324.13PBYIPuma Biotechnology0.101.731.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%BSTCBioSpecifics Technologies60.34%MGTAMagenta Therapeutics47.53%MORFMorphic94.25%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%BSTCBioSpecifics Technologies15.70%MGTAMagenta Therapeutics15.18%MORFMorphic25.60%PBYIPuma Biotechnology23.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90240.98 million229.42 millionOptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableMGTAMagenta Therapeutics6760.67 million51.46 millionNot OptionableMORFMorphic10050.09 million37.27 millionOptionablePBYIPuma Biotechnology20050.37 million38.64 millionOptionablePBYI, BSTC, ARDX, MORF, and MGTA HeadlinesRecent News About These CompaniesPBYI Surges 30% in 3 Months: How Should You Play the Stock?September 15 at 1:46 PM | zacks.com79,101 Shares in Puma Biotechnology, Inc. $PBYI Bought by Nuveen LLCSeptember 8, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Rating Increased to Strong-Buy at Wall Street ZenSeptember 8, 2025 | marketbeat.comAre Strong Financial Prospects The Force That Is Driving The Momentum In Puma Biotechnology, Inc.'s NASDAQ:PBYI) Stock?September 4, 2025 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | businesswire.comPuma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | businesswire.comAmerican Century Companies Inc. Has $3.40 Million Holdings in Puma Biotechnology, Inc. $PBYISeptember 2, 2025 | marketbeat.comPuma Biotech (PBYI) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowSeptember 1, 2025 | zacks.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?August 28, 2025 | zacks.comVirtus Advisers LLC Makes New Investment in Puma Biotechnology, Inc. $PBYIAugust 27, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Upgraded by Wall Street Zen to Buy RatingAugust 18, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Boosts Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)August 16, 2025 | marketbeat.comAdditional Considerations Required While Assessing Puma Biotechnology's (NASDAQ:PBYI) Strong EarningsAugust 15, 2025 | finance.yahoo.comPuma Biotechnology Reports Strong Q2 2025 EarningsAugust 13, 2025 | msn.comBarclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PTAugust 12, 2025 | msn.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?August 12, 2025 | zacks.comPuma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?August 12, 2025 | zacks.comResults: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New ForecastsAugust 10, 2025 | finance.yahoo.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | msn.comPBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive RevenuesAugust 8, 2025 | zacks.comPuma (PBYI) Q2 Revenue Rises 11%August 8, 2025 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBYI, BSTC, ARDX, MORF, and MGTA Company DescriptionsArdelyx NASDAQ:ARDX$6.53 -0.08 (-1.21%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$6.54 +0.01 (+0.15%) As of 06:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.BioSpecifics Technologies NASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.Magenta Therapeutics NASDAQ:MGTAMagenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Morphic NASDAQ:MORFMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Puma Biotechnology NASDAQ:PBYI$4.64 +0.17 (+3.80%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$4.64 0.00 (0.00%) As of 05:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
